Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis

Patients with idiopathic pulmonary fibrosis (IPF) occasionally experience acute exacerbations after surgery for lung cancer. Several recent studies have revealed a prophylactic effect of perioperative pirfenidone treatment on postoperative acute exacerbations of IPF in patients with lung cancer. A 75-year-old woman consulted with her pulmonologist because of an IPF shadow detected by follow-up chest computed tomography 2 months after surgical treatment of biliary cancer. Another 7 months later, chest computed tomography showed a 23- × 14-mm nodule located in the right lower lobe with high accumulation of fluorodeoxyglucose detected by positron emission tomography, resulting in a radiological diagnosis of primary lung cancer with IPF. We administered perioperative pirfenidone treatment followed by right lower lobectomy using uniportal video-assisted thoracoscopic surgery after attaining a pathological diagnosis of adenocarcinoma. The patient developed no acute exacerbations of IPF during the postoperative period, and she had no recurrence of lung cancer for 15 months after surgery. We successfully used a combination of perioperative antifibrotic medication and minimally invasive surgery after lung cancer surgery in a patient with IPF.

Download Full-text

Atrial Arrhythmia Strikes 13% After Lung Cancer Surgery

Hospitalist News ◽

10.1016/s1875-9122(10)70060-2 ◽

2010 ◽

Vol 3 (3) ◽

pp. 4

Author(s):

MITCHEL L. ZOLER

Keyword(s):

Lung Cancer ◽

Lung Cancer Surgery ◽

Cancer Surgery ◽

Atrial Arrhythmia

Download Full-text

The Volume-Outcome Relationship in Lung Cancer Surgery: The Impact of the Social Determinants of Healthcare Delivery

Journal of Thoracic and Cardiovascular Surgery ◽

10.1016/j.jtcvs.2021.02.104 ◽

2021 ◽

Author(s):

Sidra N. Bonner ◽

Elliot Wakeam

Keyword(s):

Lung Cancer ◽

Social Determinants ◽

Healthcare Delivery ◽

Lung Cancer Surgery ◽

Cancer Surgery ◽

Outcome Relationship ◽

The Social ◽

Volume Outcome ◽

The Impact

Download Full-text

Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function

BMC Pulmonary Medicine ◽

10.1186/s12890-021-01489-4 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Xiyue Zhang ◽

Wei Li ◽

Chunyan Li ◽

Jie Zhang ◽

Zhenzhong Su

Keyword(s):

Lung Cancer ◽

Lung Function ◽

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

High Resolution Computed Tomography ◽

Chemotherapeutic Regimen

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with unclear pathogenesis. IPF is considered as a risk factor for lung cancer. Compared to other lung cancers, small-cell lung cancer (SCLC) has a lower incidence, but has a more aggressive course. Patients with IPF and SCLC have a lower survival rate, more difficult treatment, and poorer prognosis. Case presentation Case 1 was of a 66-year-old man with IPF for 5 years, who was admitted to our hospital for dyspnea. Case 2 was of a 68-year-old woman, who presented with chest pains, cough, and dyspnea. Both patients had extremely poor lung function. High-resolution computed tomography and pathology revealed that both patients had IPF and SCLC. Chemotherapy comprising nedaplatin (80 mg/m2) and etoposide (100 mg for 5 days) was initiated for both patients. Antifibrotic agents were continued during the chemotherapeutic regimen. Both patients showed improvement in their condition after treatment. Conclusion The favorable outcomes in these 2 cases suggests that chemotherapy is worth considering in the management of patients having SCLC and IPF with poor lung function.

Download Full-text